Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients

Antiviral Research

Volumn 40, Issue 3, 1999, Pages 115-138

  King, Susan M ^a  

^a Hospital for Sick   (Canada)

Author keywords

Antiviral agents; Cytomegalovirus infections; Immunoglobulins; Transplants

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; LOBUCAVIR; METHYLPREDNISOLONE; OKT 3; VALACICLOVIR;

BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; EARLY DIAGNOSIS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; META ANALYSIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SURVIVAL;

CYTOMEGALOVIRUS;

EID: 0033046131     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00050-3     Document Type: Article

References (136)

1. Abecassis M.M., Koffron A.J., Buckingham M., Kaufman D.B., Fryer J.P., Stuart J., Stuart F.P. Role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for development of disease and should PCR be used to guide antiviral therapy? Transplant. Proc. 29:1997;800-801.
2. Abecassis M.M., Koffron A.J., Kaplan B.et al. The role of PCR in the diagnosis and management of CMV in solid organ recipients. Transplantation. 63:1997;275-279.
3. Aguado J.M., Gomez-Sanchez M.A., Lumbreras C.et al. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob. Agents Chemother. 39:1995;1643-1645.
4. Aschan J., Ringden O., Ljungman P., Lonnqvist B., Ohlman S. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand. J. Infect. Dis. 24:1992;143-150.
5. Atkinson K., Downs K., Golenia M., Biggs J., Marshall G., Dodds A., Concannon A. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br. J. Haematol. 79:1991;57-62.
6. Bacigalupo A., Tedone E., Sanna M.A.et al. CMV infections following allogeneic BMT: risk factors, early treatment and corelation with transplant related mortality. Haematologica. 77:1992;507.
7. Bacigalupo A., van Lint M.T., Tedone E.et al. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant. 13:1994;753-758.
8. Bacigalupo A., Bregante S., Tedone E.et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation. 62:1996;376-380.
9. Badas A., Stoukides C.A. Guidelines for prophylaxis of cytomegalovirus disease in bone marrow transplant patients. Ann. Pharmacother. 30:1996;1483-1486.
10. Badley A.D., Seaberg E.C., Porayko M.K.et al. Prophylaxis of cytomegalovirus infection in liver transplantation. Transplantation. 64(1):1997;66-73.
11. Bailey T.C., Trulock E.P., Ettinger N.A., Storch G.A., Cooper J.D., Powderly W.G. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J. Infect. Dis. 165:1992;548-552.
12. Bailey T.C., Ettinger N.A., Storch G.A.et al. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of soldi organ transplants. Am. J. Med. 95:1993;273-278.
13. Balfour H.H., Chace B.A., Stapleton J.T., Simmons R.L., Fryd D.S. A randomized, placebo controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. New Engl. J. Med. 320:1989;1381-1387.
14. Bass, E.B., Powe, N.R., Goodman, S.N., et al., 1993. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant. 12, 273-282.
15. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantion: a randomized double-blind study. Blood. 88(10):1996;4063-4071.
16. Boeckh M., Stevens-Ayers T., Bowden R.A. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J. Infect. Dis. 174:1996;907-912.
17. Bowden R.A., Sayers M., Flournoy N.et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. New Engl. J. Med. 314:1986;1006-1010.
18. Bowden R.A., Fisher L.D., Rogers K., Cays M., Meyers J.D. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J. Infect. Dis. 164:1991;483-487.
19. Bowden R.A., Slichter S.J., Sayers M.et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusu=ion-associated CMV infection aftre marrow transplant. Blood. 86:1996;3593-3603.
20. Carrieri G., Jordan M.L., Shapiro R.et al. Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients. Transplant. Proc. 27(1):1995;961-963.
21. Cohen A.T., O'Grady J.G., Sutherland S.et al. Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults. J. Med. Virol. 40(1):1993;5-9.
22. Collins L.A., Samore M.H., Roberts M.S.et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J. Infect. Dis. 170:1994;644-652.
23. Condie R., O'Reilly R.J. Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. Am. J. Med. 76:1984;134-141.
24. Conti, D.J., Freed, B.M., Lempert, N., 1993. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease. Transplant. Proc. 25, 1421-1422.
25. Conti D.J., Freed B.M., Gruber S.A., Lempert N. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. Arch. Surg. 129:1994;443-447.
26. Conti D.J., Freed B.M., Singh T.P., Gallichio M., Gruber S.A., Lempert N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch. Surg. 130:1995;1217-1222.
27. Cope A.V., Sabin C., Burroughs A.et al. Interrelationships among quality of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J. Infect. Dis. 176:1997;1484-1490.
28. Cope A.V., Sweny P., Sabin C.et al. Quality of cytomegalovirus viruia is a major risk factor for cytomegalovirus disease after renal transplantation. J. Med. Virol. 52:1997;200-205.
29. Dickinson B.I., Gora-Harper M.L., McCraney S.A., Gosland M. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Ann. Pharmacother. 30:1996;1452-1464.
30. Drew W.L., Minor R.C., Busch D.F.et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:1991;716-719.
31. Dummer J.S., Montero C.G., Griffith B.P.et al. Infections in heart-lung transplant recipients. Transplantation. 41(6):1986;725-729.
32. Duncan S.R., Grgurich W.F., Iacono A.T.et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am. J. Respir. Crit. Care Med. 150:1994;146-152.
33. Dunn D.L., Gillingham K.J., Kramer M.A.et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation. 57(6):1994;876-884.
34. Einsele H., Steidle H., Valbracht A.et al. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood. 77:1991;1104.
35. Einsele H., Ehninger G., Hebart H.et al. Polyerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therpay after bone marrow transplantation. Blood. 86(7):1995;2815-2820.
36. Eisenmann, D., Knipp, H., Laube, H., Stegmann, T., 1990. Prevention of cytomegalovirus disease in heart transplant recipients by prophylaxis with cytomegalovirus hyperimmune globulin plus oral acyclovir. Transplant. Proc. 22(5), 2322-2323.
37. Elfenbein G., Krischer J., Rand K.et al. Preliminary results of a multi-center trial to prevent death from cytomegalovirus pneumonia with intravenous immunoglobulin after allogeneic bone marrow transplantation. Transplant. Proc. 19(Suppl. 7):1987;138-143.
38. Enright H., Haake R., Weisdorf D.et al. Cytomegalovirus pneumonia aftre bone marrow transplantation. Risk factors and response to therapy. Transplantation. 55:1993;1339-1346.
39. Erice A., Jordan M.C., Chace B.A.et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA. 257(22):1987;3082-3087.
40. Erice A., Gil-Roda C., Perez J.L.et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175(5):1997;1087-1092.
41. Falagas M.E., Snydman D.R., Griffith J.et al. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Clin. Infect. Dis. 23:1996;468-474.
42. Fassbinder, W., Bechstein, P.B., Scheuermann, E.H., Schoeppe, W., 1985. Incidence of cytomegalovirus-infection after renal transplantation and first experiences with prophylactic hyperimmunoglobulin. Scan. J. Urol. Nephrol. 92 (suppl.) 23-28.
43. Fassbinder, W., Ernst, W., Hanke, P., Schoeppe, W., 1986. Cytomegalovirus infections after renal transplantation: effect of prophylactic hyperimmunoglobulin. Transplant. Proc. 18, 1393-1396.
44. Fletcher, C.V., Chinnock, B.J., Chase, B., 1988. Pharmacokinetics and safety of high-dose oral acyclovir for suppression of CMV disease after renal transplantation. Clin. Pharmacol. Ther. 44, 158-163.
45. Gane E., Saliba F., Valdecasas G.J.C.et al. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet. 350:1997;1729-1733.
46. Glenn, J., 1981. Cytomegalovirus infections following renal transplantation. Rev. Infect. Dis. 3, 1151-1178.
47. Glowacki L.S., Smaill F.M. Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease. Transplant. Proc. 25(1):1993;1408-1410.
48. Gluckman E., Devergie A., Melo R.et al. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet. 24:1983;706-708.
49. Goodrich J.M., Mori M., Gleaves C.A.et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl. J. Med. 325:1991;1601-1607.
50. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118:1993;173-178.
51. Goodrich J.M., Boeckh M., Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin. Infect. Dis. 19:1994;287-298.
52. Gor D., Sabin C., Prentice H.G.et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant. 21:1998;597-605.
53. Graham-Pole J., Camitta B., Casper J.et al. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. Bone Marrow Transplant. 3:1988;559-566.
54. Grattan M.T., Moreno-Cabral C.E., Starnes V.A.et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 261(24):1989;3561-3566.
55. Green M., Reyes J., Nour B., Beatty D., Kaufman M., Wilson J., Todo S., Tzakis A. Randomized trial of ganciclovir followed by high-dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis. Transplant. Proc. 26(1):1994;173-174.
56. Griffiths P.D. Prophylaxis against CMV infection in transplant patients. J. Antimicrob. Chemother. 39:1997;299-301.
57. Grundy J.E., Shanley J.D., Griffiths P.D. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet. October 31:1987;996-999.
58. Guglielmo B.J., Wong-Beringer A., Linker C.A. Immune globulin therapy in allogeneic bone marrow transplant: A critical review. Bone Marrow Transplant. 13:1994;499-510.
59. Hadley S., Samore M.H., Lewis W.D.et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation. 59:1995;851-859.
60. Ham J.M., Shelden S.L., Godkin R.R., Posner M.P., Fisher R.A. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction. Transplant. Proc. 27(5, Suppl. 1):1995;31-33.
61. Havel, M., Teufelsbauer, H., Laczkovics, A., et al., 1990. Cytomegalovirus hyperimmuonglobulin prophylaxis in the prevention of cytomegalovirus infection in immunosuppressed heart transplant patients. Transplant. Proc. 22 (4), 1805-1806.
62. Hebart H., Schroder A., Loffler J.et al. Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. J. Infect. Dis. 175:1997;1490-1493.
63. Hibberd P.L., Tolkoff-Rubin N.E., Conti D.et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann. Intern. Med. 123:1995;18-26.
64. Ippoliti C., Morgan A., Warkentin D.et al. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. BMT. 20:1997;491-495.
65. Kasiske, B.L., Heim-Duthoy, K.L., Tortorice, K.L., et al., 1989. Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. Arch. Intern. Med. 149, 2733-2736.
66. Khawand, N., Light, J.A., Brems, W., Aquino, A., Ali, A., 1989. Does intravenous immunoglobulin prevent primary cytomegalovirus disease in kidney transplant recipients ? Transplant. Proc. 21, 2072-2074.
67. King S.M., Superina R., Andrews W., Winston D.J., Dunn S., Busuttil R.W., Colombani P., Paradis K. Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. Clin. Infect. Dis. 25:1997;1173-1179.
68. Kubanek, B., Ernest, P., Ostendorf, P., Schafer, U., Wolf, H., 1985. Preliminary data of a controlled trial of intravenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients. Transplant. Proc. 17, 468-469.
69. Ljungman P., Oberg G., Aschan J.et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 18:1996;565-568.
70. Lumbreras C., Otero J.R., Herrero J.A.et al. Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob. Agents Chemother. 37(11):1993;2490-2492.
71. Martin M. Prophylactic cytomegalovirus management strategies. Transplant. Proc. 27(5, Suppl. 1):1995;23-27.
72. Martin M., Manez R., Linden P.et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation. 58(7):1994;779-785.
73. Merigan T.C., Renlund D.G., Keay S.et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. New Engl. J. Med. 326:1992;1182-1186.
74. Messori A., Rampazzo R., Scroccaro G., Martini N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Bone Marrow Transplant. 13:1994;163-167.
75. Meyers J.D., Leszczynski J., Zaia J.A.et al. Prevention of cytomeglovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann. Intern. Med. 98:1983;442-446.
76. Meyers J.D., Flournoy N., Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 153(3):1986;478-488.
77. Meyers J.D., Reed E.C., Shepp D.H.et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. New Engl. J. Med. 318:1988;70-75.
78. Meyers J.D., Ljungman P., Fisher L.D. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: Importance of cytomegalovirus viremia. J. Infect. Dis. 162:1990;373-380.
79. Miller, W.J., McCullough, J., Balfour, H.H., et al., 1991. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant. 7, 227-234.
80. Nakazato P.Z., Burns W., Moore P.et al. Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and ganciclovir. Transplant. Proc. 25(2):1993;1935-1937.
81. O'Grady J.G., Alexander G.J., Sutherland S.et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile duct syndrom after liver transplantation. Lancet. 2:1988;302-305.
82. Paya C.V. Role of immunoglobulins and new antivirals in treatment of cytomegalovirus infection. Transplant. Proc. 27(5, Suppl. 1):1995;28-30.
83. Paya C.V., Hermann P.E., Weisner R.H.et al. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 orthotopic liver transplantations. J. Infect. Dis. 160:1989;752-758.
84. Paya C.V., Wiesner R.H., Hermans P.E.et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J. Hepatol. 18:1993;185-195.
85. Petersen F.B., Bowden R.A., Thornquist M.et al. The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. Bone Marrow Transplant. 2:1987;141-147.
86. Plotkin S.A., Drew W.L., Felsentein D., Hirsch M.S. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J. Infect. Dis. 152:1985;833-834.
87. Pouteil-Noble C., Megas F., Chapuis F.et al. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: A randomized, controlled trial. Transplant. Proc. 28(5):1996;2811.
88. Prentice H.G., Gluckman E., Powles R.L.et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet. 343:1994;749-753.
89. Prentice H.G., Gluckman E., Powles R.L.et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. Bone Marrow Transplant. 19:1997;129-133.
90. Prian G.W., Koep L.J. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir. Transplant. Proc. 26(5, Suppl. 1):1994;54-55.
91. Przepiorka D., Ippoliti C., Panina A.et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant. 13:1994;461-464.
92. Rand K.H., Pollard R.B., Merigan T.C. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. New Engl. J. Med. 298:1978;961-963.
93. Reusser P., Fisher L.D., Buckner C.D., Thomas E.D., Meyers J.D. cytomegalovirus infection after autologous bone marrow transplantation: Occurrence of cytomegalovirus disease and effect on engraftment. Blood. 75(9):1990;1888-1894.
94. Reusser P., Gambertoglio J.G., Lilleby K., Meyers J.D. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J. Infect. Dis. 166:1992;473-479.
95. Reusser P., Cordonnier C., Einsele H.et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 17(5):1996;813-817.
96. Richardson W.P., Colvin R.B., Cheeseman S.H.et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. New Engl. J. Med. 305:1981;57.
97. Ringden O., Pihlstedt P., Volin L.et al. Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant. 2:1987;299-305.
98. Rosen H.R., Benner K.G., Flora K.D.et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation. 63(3):1997;476-478.
99. Rubie H., Attal M., Campardou A.M.et al. Risk factors for cytomegalovirus infection in bone marrow transplantation recipients transfused exclusively with seronegative blood products. Bone Marrow Transplant. 11:1993;209-214.
100. Rubin R.H. Preemptive therapy in immunocompromised hosts. New Eng. J. Med. 324(15):1991;1957-2059.
101. Rubin, R.H., 1994. Infection in the organ transplant recipient. In: Rubin, R.H., Young, L.S. (Eds), Clinical Approach to Infection in the Immunocompromised Host, 3rd ed. Plenum Press, New York, p. 629.
102. Saliba F., Eyraud D., Samuel D.et al. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant. Proc. 25(1):1993;1444-1445.
103. Schmidt G.M., Horak D.A., Niland J.C.et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. New Engl. J. Med. 324(15):1991;1005-1011.
104. Shepp D.H., Dandliker P.S., de Miranda P.et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine in the treatment of cytomegalovirus pneumonia. Ann. Intern. Med. 103:1985;368-373.
105. Siadak M.F., Kopecky K., Sullivan K.M. Reduction in transplant-related complications in patients given intravenous immune globulin after allogeneic marrow transplantation. Clin. Exp. Immunol. 97(Suppl. 1):1994;53-57.
106. Singh N., Yu V.L., Mieles L., Wagener M.M., Miner R.C., Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann. Intern. Med. 120:1994;375-381.
107. Smyth R.L., Scott J.P., Borysiewicz L.K.et al. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment. J. Infect. Dis. 164:1991;1045-1050.
108. Snydman D.R. Cytomegalovirus prophylaxis strategies in high-risk transplantation. Transplant. Proc. 26(5, Suppl. 1):1994;20-22.
109. Snydman D.R., Werner B.G., Heinze-Lacey B.et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. New Engl. J. Med. 317(17):1987;1049-1054.
110. Snydman, D.R., Werner, B.G., Tilney, N.L., et al., 1991. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: comparison of the randomized and open label trials. Transplant. Proc. 123, 1357-1360.
111. Snydman D.R., Werner B.G., Dougherty N.N.et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. Ann. Intern. Med. 119:1993;984-991.
112. Snydman D.R., Werner B.G., Dougherty N.N.et al. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Transplant. Proc. 26(5, Suppl. 1):1994;23-27.
113. Steinmuller, D.R., Graneto, D., Swift, C., et al., 1989. Use of intravenous immunoglobulin prophylaxis for primary cytomegalovirus infection post living-related-donor renal transplantation. Transplant. Proc. 21, 2069-2071.
114. Steinmuller, D.R., Novick, A.C., Streem, S.B., et al., 1990. Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection. Transplant. 49, 68-70.
115. Startta R.J., Sheafer M.S., Markin R.S.et al. Clinical patterns of cytomegalovirus disease after transplantation. Arch. Surg. 124:1989;1433-1450.
116. Stratta R.J., Shaefer M.S., Cushing K.A.et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch. Surg. 127:1992;55-64.
117. Sullivan K.M., Kopecky K.J., Jocom J.et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. New Engl. J. Med. 323:1990;705-712.
118. van der Meer J.T.M., Drew W.L., Bowden R.A.et al. Summary of the international consensus symposium on advances in the diagnosis, treatment and prophylaxis of cytomegalovirus infection. Antiviral Res. 32:1996;119-140.
119. Vasquez, E.M., Sanchez, J., Pollak, R., et al., 1993. High dose oral acyclovir prophylaxis for primary cytomegalovirus infection in seronegative renal allograft recipients. Transplant. 55 (2), 448-50.
120. Verdonck L.F., Dekker A.W., Rozenberg-Arska M., van den Hoek M.R. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin. Infect. Dis. 24:1997;901-907.
121. von Bueltzingsloewen A., Bordigoni P., Witz F., Bene M.C., Schmitt C., Lacour B., Sommelet D. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 12:1993;197-202.
122. Vu Van H., Fiere D., Chomel J.et al. Prophylaxis against cytomegalovirus infection after BMT with gammaglobulins. Exp. Hematol. 13(Suppl. 17):1985;105.
123. Wingard J.R., Yen-Hung Chen D., Burns W.H.et al. Cytomegalovirus infection after autologous transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood. 71:1988;1432.
124. Winston D.J. Prevention of cytomegalovirus in transplant recipients. Lancet. 346:1995;1380-1381.
125. Winston D.J., Pollard R.B., Ho W.G.et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann. Intern. Med. 97:1982;11-18.
126. Winston, D.J., Ho, W.G., Lin, C.H., et al., 1984. Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of controlled trial. Am. J. Med. 76, 128-133.
127. Winston D.J., Ho W.G., Lin C.H.et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann. Intern. Med. 106:1987;12-18.
128. Winston D.J., Ho W.G., Bartoni K.et al. Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev. Infect. Dis. 10(suppl 3):1988;S547-S553.
129. Winston D.J., Ho W.G., Champlin R.E. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis. 12:1990;S776-S792.
130. Winston D.J., Ho W.G., Bartoni K., Champlin R.E. Intravenous immunoglobulins and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant. 12:1993;283-288.
131. Winston D.J., Ho W.G., Bartoni K.et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann. Intern. Med. 118:1993;179-184.
132. Winston D.J., Imagawa D.K., Holt C.D., Kaldas F., Shaked A., Busuttil R.W. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation. 60(11):1995;1357-1360.
133. Winston D.J., Wirin D., Shaked A., Busuttil R.W. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet. 346:1995;69-74.
134. Wittes J.T., Kelly A., Plante K.M. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. Transplant. Proc. 28(6, Suppl 2):1996;17-24.
135. Wolf D.G., Spector S.A. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation. 56:1993;330.
136. Yau J.C., Dimopoulos M.A., Huan S.D.et al. Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. Eur. J. Haematol. 47:1991;371-376.